chemical:lixisenatide
Adlyxin's 2025 Patent expiry
Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.
Latest
categeory:watercooler
Research models applied to GLP1s and Plateaus
New research that shows a benefit to appetite feedback control circuits via mathematical modeling, showing the benefits of using GLP1s.
22.7% weight loss yet Novo Nordisk stock drops 27%
Novo Nordisk's new CagriSema drug showed weight loss results that are *stunning*, but less than what Wall Street expected.
chemical:semaglutide
Semaglutide & Liraglutide continue to be effective
Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.
category:watercooler
Lizzo's as a lens on GLP1 public opinion
We view the the reflection of public opinion on GLP1s and drugs like Ozempic, Mounjaro, and Zepbound through an unusual lens: Lizzo.
company:eli-lilly
Eli Lilly brands GLP1s as "anti-hedonics"
Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"
category:watercooler
How much are people paying for GLP1s? (2024/11)
We take another look at reports of what people are paying for GLP1s with/without insurance and everywhere in between.
category:factsheet
A list of FDA approved GLP1s
A list of FDA approved GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc), for easy reference.
category:side-effects
Anxiety and suicidal thoughts after stopping GLP1s?
Reports of anxiety and suicidal reports have been reported for people after *stopping* use of GLP1s. We dig in, and weight the FDA's comments.
government
Biden-Harris administration keen on GLP1s
The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.
category:watercooler
Weight loss "stalling" on GLP1s?
What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.
country:uk
The UK's bet on GLP1
A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.